We believe that these agents are sometimes prescribed without a complete evaluation for prostate cancer, based on our clinical experience of encountering patients treated on the basis of elevated prostate specific antigen (PSA) levels alone. This evidence concerns the gene KLK3 and prostate carcinoma.